STOKE THERAPEUTICS INC (STOK) Stock Price & Overview
NASDAQ:STOK • US86150R1077
Current stock price
The current stock price of STOK is 37.27 USD. Today STOK is up by 5.46%. In the past month the price increased by 12.29%. In the past year, price increased by 384.66%.
STOK Key Statistics
- Market Cap
- 2.205B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.04
- Dividend Yield
- N/A
STOK Stock Performance
STOK Stock Chart
STOK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to STOK. When comparing the yearly performance of all stocks, STOK is one of the better performing stocks in the market, outperforming 98.51% of all stocks.
STOK Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to STOK. While STOK has a great health rating, there are worries on its profitability.
STOK Earnings
On January 12, 2026 STOK reported an EPS of -0.97 and a revenue of 1.40M. The company missed EPS expectations (-33.26% surprise) and missed revenue expectations (-76.63% surprise).
STOK Forecast & Estimates
18 analysts have analysed STOK and the average price target is 43.96 USD. This implies a price increase of 17.96% is expected in the next year compared to the current price of 37.27.
For the next year, analysts expect an EPS growth of -8430.74% and a revenue growth -82.83% for STOK
STOK Groups
Sector & Classification
STOK Financial Highlights
Over the last trailing twelve months STOK reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 97.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.65% | ||
| ROE | -1.95% | ||
| Debt/Equity | 0 |
STOK Ownership
STOK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 369.653B | ||
| AMGN | AMGEN INC | 15.56 | 188.346B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 171.971B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.65 | 110.812B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.01 | 78.867B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.37 | 42.456B | ||
| INSM | INSMED INC | N/A | 30.821B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.581B | ||
| NTRA | NATERA INC | N/A | 27.795B | ||
| BIIB | BIOGEN INC | 11 | 25.833B | ||
| UTHR | UNITED THERAPEUTICS CORP | 20.13 | 25.444B | ||
| MRNA | MODERNA INC | N/A | 21.686B | ||
| INCY | INCYTE CORP | 12.64 | 18.97B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About STOK
Company Profile
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 170 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Company Info
IPO: 2019-06-19
STOKE THERAPEUTICS INC
45 Wiggins Avenue
Bedford MASSACHUSETTS 01730 US
CEO: Edward M. Kaye
Employees: 170
Phone: 13025310855
STOKE THERAPEUTICS INC / STOK FAQ
What does STOK do?
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 170 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Can you provide the latest stock price for STOKE THERAPEUTICS INC?
The current stock price of STOK is 37.27 USD. The price increased by 5.46% in the last trading session.
Does STOK stock pay dividends?
STOK does not pay a dividend.
What is the ChartMill rating of STOKE THERAPEUTICS INC stock?
STOK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for STOKE THERAPEUTICS INC?
The Revenue of STOKE THERAPEUTICS INC (STOK) is expected to decline by -82.83% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does STOKE THERAPEUTICS INC have?
STOKE THERAPEUTICS INC (STOK) currently has 170 employees.
Can you provide the market cap for STOKE THERAPEUTICS INC?
STOKE THERAPEUTICS INC (STOK) has a market capitalization of 2.20B USD. This makes STOK a Mid Cap stock.